ARTICLE | Clinical News
Stelara ustekinumab regulatory update
October 3, 2016 7:00 AM UTC
FDA approved Stelara ustekinumab from Johnson & Johnson’s Janssen Biotech Inc. unit to treat moderately to severely active Crohn’s disease in adults. Stelara is indicated in CD patients who failed or were intolerant to immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker or who failed or were intolerant to >=1 TNF blocker. ...